The Kinase Inhibitor Fasudil (HA-1077) Reduces Intimal Hyperplasia through Inhibiting Migration and Enhancing Cell Loss of Vascular Smooth Muscle Cells
- 19 August 1999
- journal article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 262 (1), 211-215
- https://doi.org/10.1006/bbrc.1999.1129
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitorDiabetologia, 1997
- Possible prophylactic potential of HA1077, a Ca2+ channel antagonist and vasodilator, on chronic cerebral vasospasmEuropean Journal of Pharmacology, 1992
- Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhageJournal of Neurosurgery, 1992
- Prevention of restenosis after percutaneous transluminal coronary angioplasty: The search for a “magic bullet”American Heart Journal, 1991
- An increase or a decrease in myosin II phosphorylation inhibits macrophage motility.The Journal of cell biology, 1991
- Effects of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscleEuropean Journal of Pharmacology, 1991
- Inhibition of myosin light chain phosphorylation in cultured smooth muscle cells by HA1077, a new type of vasodilatorBiochemical and Biophysical Research Communications, 1990
- Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferationJournal of the American College of Cardiology, 1990
- Pathological changes induced by repeated percutaneous transluminal coronary angioplasty.Heart, 1987
- Regulation of contractile proteins by phosphorylation.JCI Insight, 1983